{
  "input": {
    "mode": "execute_actions",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "items": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "慢性炎症相关风险",
            "expectation": "如果风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "慢性炎症相关风险",
            "expectation": "如果风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ]
      },
      {
        "hypothesis_id": "H3",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "慢性炎症相关风险",
            "expectation": "如果风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          }
        ]
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "t_tnf_inhibition",
          "type": "Target",
          "label": "TNF Inhibition",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "t_il_17_pathway",
          "type": "Target",
          "label": "IL-17 Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "t_il_23_pathway",
          "type": "Target",
          "label": "IL-23 Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "p_psoriasis_pathway",
          "type": "Pathway",
          "label": "Psoriasis Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot1",
          "type": "Target",
          "label": "OffTargetInflammation",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp1",
          "type": "Pathway",
          "label": "RiskPathwayChronicInflammation",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv1",
          "type": "Phenotype",
          "label": "AdversechronicCondition",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "t_psoriasismediators",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已知作用于皮肤组织"
        },
        {
          "source": "drug_adalimumab",
          "target": "t_tnf_inhibition",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "TNF 抑制直接相关"
        },
        {
          "source": "drug_apremilast",
          "target": "t_il_17_pathway",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "与 IL-17 途径调节关联"
        },
        {
          "source": "drug_brodalumab",
          "target": "t_il_17_pathway",
          "relation": "inhibits",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对 IL-17 的抑制作用"
        },
        {
          "source": "drug_etanercept",
          "target": "t_tnf_inhibition",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接抑制 TNF"
        },
        {
          "source": "drug_guselkumab",
          "target": "t_il_23_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-23 抑制机制关联"
        },
        {
          "source": "drug_infliximab",
          "target": "t_tnf_inhibition",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "TNF 抑制剂"
        },
        {
          "source": "drug_ixekizumab",
          "target": "t_il_17_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "通过 IL-17 的抑制作用"
        },
        {
          "source": "drug_methotrexate",
          "target": "p_psoriasis_pathway",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "与银屑病治疗常识一致"
        },
        {
          "source": "drug_secukinumab",
          "target": "t_il_17_pathway",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接抑制 IL-17"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "t_il_23_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-23 抑制有效性"
        },
        {
          "source": "drug_ustekinumab",
          "target": "t_il_23_pathway",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "针对 IL-23 的抑制机制"
        },
        {
          "source": "t_tnf_inhibition",
          "target": "p_psoriasis_pathway",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "通路参与关系"
        },
        {
          "source": "t_il_17_pathway",
          "target": "p_psoriasis_pathway",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "IL-17 在皮炎过程中的角色"
        },
        {
          "source": "t_il_23_pathway",
          "target": "p_psoriasis_pathway",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "皮肤相关路径参与"
        },
        {
          "source": "p_psoriasis_pathway",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "病理学上已知关联"
        },
        {
          "source": "drug_acitretin",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_adalimumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_apremilast",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_brodalumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_etanercept",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_guselkumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_infliximab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_ixekizumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_methotrexate",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_secukinumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "直接支持适应症"
        },
        {
          "source": "n_acitretin",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_adalimumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_apremilast",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_brodalumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_etanercept",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_guselkumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_infliximab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ixekizumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_methotrexate",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_secukinumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_tildrakizumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ustekinumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ot1",
          "target": "n_rp1",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "与慢性炎症反应相关"
        },
        {
          "source": "n_rp1",
          "target": "n_adv1",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良慢性病理情况"
        },
        {
          "source": "n_adv1",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        }
      ],
      "round_index": 3
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    }
  },
  "output": {
    "hypothesis_id": "H1",
    "executed_actions": [
      {
        "action_ref": 0,
        "status": "done",
        "graph_updates": {
          "add_nodes": [],
          "add_edges": [],
          "merge": [],
          "set_weights": [],
          "conflict_hotspots": []
        },
        "notes": "已完成慢性炎症相关风险的压力测试：高权重的反驳边已连接至假设 H1、H2 和 H3"
      }
    ],
    "unexecuted_actions": [],
    "residual_conflicts": []
  }
}